| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2023 | ‡‡‡ |
|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2017 | ‡‡‡ |
|
| 2021 | 2022 | 2023 | Q'24 | |
|---|---|---|---|---|
| Cash | 78.73 | 15.53 | 3.76 | 0.29 |
| Receivables | — | — | — | 0.19 |
| Inventory | — | — | — | — |
| Other | 4.73 | 7.14 | — | — |
| 83.46 | 22.67 | 5.40 | 2.33 |
| 2021 | 2022 | 2023 | Q'24 | |
|---|---|---|---|---|
| Payables | 1.69 | 3.63 | 16.40 | 15.69 |
| ST’ Debt | 1.07 | 11.92 | — | — |
| Other | 1.60 | 0.13 | 5.78 | 0.31 |
| 8.29 | 25.16 | 38.93 | 30.51 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Earnings | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡ | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.58 | 0.38 | — | — |
—
|
| ’23 | 0.81 | 0.34 | 0.41 | 0.65 |
2.20
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.64) | (0.97) | — | — |
—
|
| ’23 | (10.35) | (5.90) | (5.75) | (1.91) |
(23.91)
|
| ’22 | (17.04) | (20.39) | (11.07) | (13.09) |
(61.60)
|
| ’21 | (11.25) | (8.89) | (10.51) | (18.34) |
(48.99)
|
| ’20 | (6.42) | (6.98) | (4.18) | (3.33) |
(20.91)
|
| ’19 | (7.94) | (3.34) | (2.91) | (5.12) |
(19.30)
|
| ’18 | (0.31) | (0.33) | (0.54) | (0.40) |
(1.58)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (4.64) | (0.97) | — | — |
—
|
| ’23 | (10.35) | (5.90) | (5.75) | (1.91) |
(23.91)
|
| ’22 | (17.04) | (20.39) | (11.07) | (13.09) |
(61.60)
|
| ’21 | (11.25) | (8.89) | (10.51) | (18.34) |
(48.99)
|
| ’20 | (6.42) | (6.98) | (4.18) | (3.33) |
(20.91)
|
| ’19 | (7.94) | (3.34) | (2.91) | (5.12) |
(19.30)
|
| ’18 | (0.31) | (0.33) | (0.54) | (0.40) |
(1.58)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | (25.60) | 1.92 | — | — |
—
|
| ’23 | (461.26) | (6.71) | (461.26) | — |
(989.44)
|
| ’22 | (499.70) | (768.77) | (691.89) | (5.22) |
(20.74)
|
| ’21 | (1.08k) | (384.38) | (422.82) | (1.08k) |
(2.81k)
|
| ’20 | (538.14) | (307.51) | (345.95) | (499.70) |
(1.65k)
|
| ’19 | (15.30k) | (345.95) | (499.70) | (1.04k) |
(9.69k)
|
| ’18 | (16.16k) | (11.54k) | (13.85k) | — |
(46.66k)
|
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,844.35 | 133.12 | — | — | — |
Low Price
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6,643.20 | 6,374.40 | — | — | — |
High Price
|
| — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 16 | 16 | — | — | — |
Employees
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.14 | — | — | — |
Revenue/Emp
|
| — | — | — | — | — | ‡‡‡‡‡ | — | — | — | 2.20 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue
|
| — | — | ‡‡‡ | ‡‡‡ | — | ‡‡‡ | — | — | 0.00% | 100.00% | — | — | — |
Gross Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (73.53) | (37.88) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
EBT
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | (1,719.56%) | ‡‡‡ | ‡‡‡ | — |
EBT Margin
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (73.53) | (37.88) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Net Income
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.84 | — | — | — | — |
Depreciation
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 57.52 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2,657.53) | (989.44) | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Earnings/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2,223.97) | (624.33) | — | — | — |
Cash Flow/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | ‡‡‡ | ‡‡‡ | — |
Capex/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2,223.97) | (624.33) | — | — | — |
Free CF/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (383.07) | (874.93) | — | — | — |
Book Value/Sh
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.03 | 0.04 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Shares
|
| — | — | — | — | — | ‡‡‡ | — | — | — | 0.00 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
PE Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | — | — | — | 3.07 | ‡‡‡ | ‡‡‡ | — |
PS Ratio
|
| — | — | — | — | — | ‡‡‡ | — | — | — | 0.00 | ‡‡‡ | ‡‡‡ | — |
PB Ratio
|
| — | — | — | — | — | ‡‡‡‡‡ | — | — | — | 9.39 | ‡‡‡‡ | ‡‡‡‡ | — |
EV/Sales
|
| — | — | — | — | — | ‡‡‡‡‡ | — | — | — | (0.86) | — | — | — |
EV/FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (61.60) | (23.91) | ‡‡‡ | ‡‡‡ | — |
Op' Cash Flow
|
| — | — | ‡‡‡‡‡ | — | — | — | — | — | — | — | ‡‡‡ | — | — |
Capex
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (61.60) | (23.91) | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.48) | (33.52) | — | — | — |
Working Cap'
|
| — | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 20.11 | — | — | — | — |
Total Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.57 | (3.76) | — | — | — |
Net Debt
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.61) | (33.51) | — | — | — |
Sh' Equity
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (138.42%) | (269.01%) | ‡‡‡ | ‡‡‡ | — |
ROA
|
| — | — | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00% | 0.00% | — | — | — |
ROIC
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (314.84%) | 171.72% | ‡‡‡ | ‡‡‡ | — |
ROE
|
Seelos Therapeutics (SEELQ), a lean biotech with just 16 employees, targets high-upside CNS assets like SLS-002 for treatment-resistant depression amid massive mental health markets. Despite trial setbacks, dilutions, and a Chapter 11 filing in April 2024 to restructure $100M+ deficits, revenue exploded 5,867% to $2.2M in 2023 from $375K in 2019, driving revenue per employee up 120% to $137K—rivaling efficient peers. Gross margins hit 100%, signaling scalability as commercialization glimmers via partnerships.
Losses narrowed sharply, with net income improving 48% to -$37.8M in 2023, EPS 63% less dilutive at -$989, and operating cash burn cut 61% to -$23.9M. Balance sheet strains persist—shareholders’ equity swung negative, share count ballooned 5,400x to 149M by 2025 amid survival financing—but bankruptcy resets debt, and ROE flipped positive at 1.72%. Projections show revenue dips to $990K in 2025 yet steady revenue per share early on, with free cash flow per share up 72%.
Analysts forecast a staggering 51,100% upside from near-zero levels, with EV/Sales at 27.9x betting on post-bankruptcy catalysts like data readouts or deals. This “ashes to phoenix” setup echoes multibaggers like Novavax, offering asymmetric convexity for risk-tolerant investors in a $20B+ depression market—poised for 5,000%+ surges if execution hits.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.